1
|
Guo F, Yuan D, Zhang J, Zhang H, Wang C, Zhu L, Zhang J, Pan Y, Shao C. Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State. Front Cell Dev Biol 2019; 7:238. [PMID: 31750299 PMCID: PMC6843082 DOI: 10.3389/fcell.2019.00238] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Accepted: 10/01/2019] [Indexed: 12/21/2022] Open
Abstract
Recently, a growing number of ADP ribosylation factor (ARF) family members has been suggested to be critical in tumorigenesis. However, the effects of most ARF members on lung adenocarcinoma pathogenesis are still not well disclosed yet. In this study, ARF-like GTPase 14 (ARL14) was screened as an important prognostic factor of lung adenocarcinoma from The Cancer Genome Atlas (TCGA) database and validated by our in vitro experiments. It was found that silencing of ARL14 gene inhibited cell proliferation and the abilities of cell migration and invasion, and it also attenuated radiation damage of lung adenocarcinoma cells but had no effect on the proliferation of normal lung cells. Notably, ARL14 siRNA blocked the extracellular signal-regulated kinase (ERK)/p38 signaling pathway and induced cell cycle arrest in G0 phase, ultimately leading to cell dormancy. Moreover, ARL14 siRNA enhanced the expression of cell death activator DFFA-like effector (CIDEC) that had opposite roles in cell proliferation and migration to ALR14. Collectively, our results suggest that ARL14 has an important role in the pathogenesis of lung adenocarcinoma through CIDEC/ERK/p38 signaling pathway, and thus it could be applied as a new candidate of prognosis indicator and/or therapeutic target of lung adenocarcinoma.
Collapse
Affiliation(s)
- Fei Guo
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Dexiao Yuan
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Junling Zhang
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Hang Zhang
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Chen Wang
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Lin Zhu
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Jianghong Zhang
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Yan Pan
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| | - Chunlin Shao
- Institute of Radiation Medicine, Fudan University, Shanghai, China
| |
Collapse
|
2
|
Jiang Y, Zhao CY, Cheng LC, Xu B, Lv HY. ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis. Hered Cancer Clin Pract 2017. [PMID: 28630657 PMCID: PMC5470195 DOI: 10.1186/s13053-017-0068-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Adenosine diphosphate (ADP)-ribosylation factor-like tumour suppressor gene 1(ARLTS1) might be associated with an increased risk of several types of familial cancers. However, previous studies have shown that cancer susceptibility is not completely consistent with ARLTS1 polymorphisms, and the precise mechanism remains unknown. Therefore, we conducted a meta-analysis of case-control studies by searching the PubMed, Embase, OVID, Science Direct and Chinese National Knowledge Infrastructure (CNKI) databases. In total, 12 studies met the inclusion criteria and were included in this meta-analysis. Statistical analyses were performed using STATA 11.0 software. Overall, the Cys148Arg T > C variant significantly increased cancer risk (CC vs. TT: OR = 1.27, 95% CI = 1.15–1.41, P < 0.05). The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18–1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12–1.43). Trp149Stop, Pro131Leu, Ser99Ser and Leu132Leu were not correlated with cancer susceptibility. Based on these results, we demonstrated that the ARLTS1 Cys148Arg polymorphism is associated with an increased risk of sporadic cancer and familial cancer, and there were no associations between the other four SNPs (i.e., Trp149Stop, Pro131Leu, Ser99Ser and Leu132Leu) and cancer risk.
Collapse
Affiliation(s)
- Yan Jiang
- Department of Pharmaceuticals, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027 People's Republic of China
| | - Chen-Yang Zhao
- Department of Pharmaceuticals, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027 People's Republic of China
| | - Li-Chun Cheng
- Department of Pharmaceuticals, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027 People's Republic of China
| | - Bing Xu
- Department of Pharmaceuticals, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027 People's Republic of China
| | - Hui-Yi Lv
- Department of Pharmaceuticals, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027 People's Republic of China
| |
Collapse
|
3
|
Hamadou WS, Besbes S, Mani R, Bourdon V, Ben Youssef Y, Achour B, Regaieg H, Eisinger F, Mari V, Gesta P, Dreyfus H, Bonadona V, Dugast C, Zattara H, Faivre L, Noguchi T, Khélif A, Sobol H, Soua Z. ARLTS1, potential candidate gene in familial aggregation of hematological malignancies. Bull Cancer 2016; 104:123-127. [PMID: 27866680 DOI: 10.1016/j.bulcan.2016.10.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 10/17/2016] [Accepted: 10/19/2016] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Genetic predisposition to familial hematological malignancies was previously described through several epidemiological analyses, but the genetic basis remains unclear. The tumor-suppressor ARLTS1 gene was previously described in sporadic hematological malignancies and familial cancer context. METHODS In this study, we sequence the ARLTS1 gene in 100 patients belonging to 88 independent Tunisian and French families. RESULTS After gene sequencing, we report 8 genetic variations, most of which were previously reported in several cancer forms. The most common variants were W149X and C148R and were previously associated to B-cell chronic lymphocytic leukemia and to high-risk of familial breast cancer. CONCLUSIONS These results emphasize the fact that ARLTS1 gene mutations can be considered as a potential predisposing factor in familial hematological malignancies and other several cancer forms.
Collapse
Affiliation(s)
- Walid Sabri Hamadou
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia.
| | - Sawsen Besbes
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia
| | - Rahma Mani
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia
| | - Violaine Bourdon
- Institut Paoli-Calmettes, département d'oncologie génétique, de prévention et dépistage, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Yosra Ben Youssef
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia; Service d'hématologie clinique, CHU Farhat Hached, Sousse, Tunisia
| | - Béchir Achour
- Service d'hématologie clinique, CHU Farhat Hached, Sousse, Tunisia
| | - Haifa Regaieg
- Service d'hématologie clinique, CHU Farhat Hached, Sousse, Tunisia
| | - François Eisinger
- Institut Paoli-Calmettes, centre de lutte contre le cancer, département d'anticipation et de suivi du cancer, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Véronique Mari
- Centre de lutte contre le cancer, centre Antoine-Lacassagne, service d'oncologie génétique, 33, avenue de Valombrose, 06100 Nice, France
| | - Paul Gesta
- Centre hospitalier Georges-Renon, service oncogénétique pour la consultation oncogénétique régionale Poitou-Charentes, 79021 Niort, France
| | - Hélène Dreyfus
- Institut Sainte-Catherine, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9, France
| | - Valérie Bonadona
- Centre Léon-Bérard, unité de génétique épidémiologique, 28, prom. Léa-et-Napoléon-Bullukian, 69008 Lyon, France
| | - Catherine Dugast
- Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - Hélène Zattara
- Hôpital de la Timone, département de génétique, 264, rue Saint-Pierre, 13385 Marseille, France
| | - Laurence Faivre
- CHU de Dijon, hôpital d'Enfants, 14, rue Paul-Gaffarel, 21079 Dijon, France
| | - Testsuro Noguchi
- Institut Paoli-Calmettes, département d'oncologie génétique, de prévention et dépistage, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Abderrahim Khélif
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia; Service d'hématologie clinique, CHU Farhat Hached, Sousse, Tunisia
| | - Hagay Sobol
- Institut Paoli-Calmettes, département d'oncologie génétique, de prévention et dépistage, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Zohra Soua
- Université de Sousse, faculté de médecine de Sousse, laboratoire de Biochimie, UR « biologie moléculaire des leucémies et lymphomes », avenue Mohamed Karoui, 4000 Sousse, Tunisia
| |
Collapse
|
4
|
Ma SH, Kim BG, Choi JY, Kim TJ, Kim YM, Kim JW, Kang S, Kang D, Yoo KY, Park SK. Korean epithelial ovarian cancer study (Ko-EVE): protocols and interim report. Asian Pac J Cancer Prev 2013; 13:3731-40. [PMID: 23098463 DOI: 10.7314/apjcp.2012.13.8.3731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND There have been few studies of Asian ovarian cancer and benign tumors. The primary aim of this paper was to report the protocol of the Ko-EVE study to examine epidemiological and molecular factors for ovarian cancer and benign neoplasms and to ascertain the major risk factors for ovarian cancer control in Korea. METHODS This case-control study covers incident epithelial ovarian cancers and benign neoplasms, four major centers participating in enrolling incident cases and 3 hospitals enrolling healthy controls among health examinees. Standardized questionnaires were administered by trained interviewers, including sections on socio-demographics characteristics, past medical history, medication usage, family history, lifetime consumption of alcohol and tobacco, diet, physical activity, and reproductive factors for women. Various biological specimens were collected in the biorepository according to the standardized protocol. Annual follow-up for cancer cases and follow-up at the 1st year for benign tumor cases are performing to evaluate treatment effect and progression. Passive follow to see long-term survival will be conducting using record linkage with national data. RESULTS The total number recruited in 2010-2011 was 246 epithelial ovarian cancer cases, 362 benign epithelial tumors and 345 controls. We are planning to collect subjects for at least 1,500 sets of ovarian cancer, 2,000 benign tumors and 1,500 controls till 2018. CONCLUSION The Ko-EVE will provide unique and important data to probe the etiology and natural history of Korean epithelial ovarian cancer. It will be continued by genomic and proteomic epidemiological analyses and future intervention studies for the prevention of ovarian cancer among Koreans.
Collapse
Affiliation(s)
- Seung Hyun Ma
- Department of Preventive Medicine, College of Medicine, Seoul National University, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Meimei L, Peiling L, Baoxin L, Changmin L, Rujin Z, Chunjie H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med Oncol 2010; 28:282-9. [PMID: 20054719 DOI: 10.1007/s12032-009-9400-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2009] [Accepted: 12/17/2009] [Indexed: 12/30/2022]
Abstract
Ovarian cancer is a leading cause of cancer-related women mortality in China. In recent years, the molecular mechanisms involved in ovarian carcinoma development and/or progression have been intensely studied, and several genes have been identified. Deleted in Colorectal Carcinoma (DCC), is an important tumor suppressor gene, which is inactivated in many kinds of tumors, and its function(s) is not clarified. Even though the lost expression of DCC occurred in later stages of multistep colorectal carcinogenesis, its contribution to the onset or progression of ovarian cancer is not fully understood. To investigate DCC expression in ovarian cancer, we studied 254 clinical samples by RT-PCR. Our results revealed that 52% malignant ovarian cancer did not express DCC gene. By contrast, DCC expression was observed in all normal ovary tissues and 80% benign ovarian tumors. Obviously, there was a significant correlation between DCC expression and ovarian cancer, especially in the epithelial ovarian cancer. The present study also suggested that the loss expression of DCC occurred more frequently in the cases of later clinical stage, higher pathological grade, and poorer prognosis. In the other part of this study, we further explored DCC expression after transfection in two kinds of ovarian cancer cell lines, namely SKOV3 cell and HO-8910 cell, using RT-PCR and immunocytochemistry. The results indicated that DCC expressed in SKOV3-DCC and HO-8910-DCC cells, and ultrastructural analysis showed the appearance of apoptotic features in them. Furthermore, cell growth was markedly down-regulated in above groups of cells, indicating that transfection with the DCC constructs can suppress the growth of tumor cells. In conclusion, our results suggest an association of lost expression of DCC with the ovarian cancer, and DCC gene may inhibit the growth of ovarian carcinoma cells. However, this result needs further trials with a larger sample.
Collapse
MESH Headings
- Adenocarcinoma, Clear Cell/genetics
- Adenocarcinoma, Clear Cell/metabolism
- Adenocarcinoma, Clear Cell/pathology
- Adenocarcinoma, Mucinous/genetics
- Adenocarcinoma, Mucinous/metabolism
- Adenocarcinoma, Mucinous/pathology
- Base Sequence
- Cell Proliferation
- Cystadenocarcinoma, Serous/genetics
- Cystadenocarcinoma, Serous/metabolism
- Cystadenocarcinoma, Serous/pathology
- DCC Receptor
- Disease Progression
- Endometrial Neoplasms/genetics
- Endometrial Neoplasms/metabolism
- Endometrial Neoplasms/pathology
- Female
- Humans
- Molecular Sequence Data
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/metabolism
- Ovarian Neoplasms/pathology
- Ovary/metabolism
- Ovary/pathology
- Prognosis
- Receptors, Cell Surface/antagonists & inhibitors
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/metabolism
- Tumor Cells, Cultured
- Tumor Suppressor Proteins/antagonists & inhibitors
- Tumor Suppressor Proteins/genetics
- Tumor Suppressor Proteins/metabolism
Collapse
Affiliation(s)
- Liu Meimei
- Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Harbin Medical University, 150086 Harbin, Hei Longjiang, China
| | | | | | | | | | | |
Collapse
|